Sugi Predict

Sugi Predict / Compounds / SCHEMBL524587

SCHEMBL524587

SCHEMBL524587

NNP(=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.46
▸ CA4 P22748 1/20 0.46
▸ CA5A P35218 1/20 0.46
▸ LMNA P02545 2/20 0.42
▸ CFTR P13569 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ ALPG P10696 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ NPY1R P25929 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPY2R P49146 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ KCNA5 P22460 1/20 0.39
▸ ALOX15 P16050 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13109422 0.78 CA2 (0.50) CA2CA4CA5ALMNACFTR
SCHEMBL524346 0.78 CA2 (0.50) CA2CA4CA5ALMNACFTR
SCHEMBL30604627 0.76 CA2 (0.48) CA2CA4CA5ALMNACFTR
Potassium SCHEMBL30627046 0.76 CA2 (0.48) CA2CA4CA5ALMNACFTR
SCHEMBL647195 0.74 CA2 (0.52) CA2CA4CA5ALMNACFTR
SCHEMBL9617518 0.74 CA2 (0.52) CA2CA4CA5ALMNACFTR
SCHEMBL27300024 0.74 CA2 (0.46) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL3949 0.74 CA2 (0.58) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL513223 0.74 CA2 (0.58) CA2CA4CA5ALMNACFTR
SCHEMBL29102141 0.73 LMNA (0.57) CA2CA4CA5ALMNACFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118185294-B Deflection-resistant cable material for drag chain equipment and preparation method thereof 玖开特种线缆(上海)有限公司 2024-09-13 — — CN claimed
CN-118185294-A Deflection-resistant cable material for drag chain equipment and preparation method thereof 玖开特种线缆(上海)有限公司 2024-06-14 — — CN claimed
CN-118059319-B Preparation method and application of swimming bladder membrane with asymmetric double-sided structure 中山大学附属口腔医院 2024-10-01 — — CN disclosed
CN-118185294-B Deflection-resistant cable material for drag chain equipment and preparation method thereof 玖开特种线缆(上海)有限公司 2024-09-13 — — CN disclosed
CN-118185294-A Deflection-resistant cable material for drag chain equipment and preparation method thereof 玖开特种线缆(上海)有限公司 2024-06-14 — — CN disclosed
CN-118059319-A Preparation method and application of swimming bladder membrane with asymmetric double-sided structure 中山大学附属口腔医院 2024-05-24 — — CN disclosed
CN-116745299-A Thienopyrimidine derivatives 正大天晴药业集团股份有限公司 2023-09-12 — — CN disclosed
CN-116710146-A Antibody molecule-drug conjugates and uses thereof 威特拉公司 2023-09-05 — — CN disclosed
EP-1999114-B1 PYRAZOLES AS 11-BETA-HSD-1 HOFFMANN LA ROCHE (CH) 2015-07-22 — — EP disclosed
US-8729163-B2 Phosphinic acid hydrazide flame retardant compositions BASF SE (DE) 2014-05-20 — — US disclosed
US-8729163-B2 Phosphinic acid hydrazide flame retardant compositions BASF SE (DE) 2014-05-20 — — US disclosed
EP-2295411-A1 Pyrazoles as 11-beta-hsd-1 F. Hoffmann-La Roche AG (CH) 2011-03-16 — — EP disclosed
US-7728029-B2 Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-06-01 — — US disclosed
EP-1999114-A2 PYRAZOLES AS 11-BETA-HSD-1 F. Hoffmann-la Roche AG (CH) 2008-12-10 — — EP disclosed
EP-1928840-A1 1H-PYRAZOLE 4-CARBOXYLAMIDES, THEIR PREPARATION AND THEIR USE AS 11BETA-HYDROXYSTEROID DEHYDROGENASE F. Hoffmann-Roche AG (CH) 2008-06-11 — — EP disclosed
US-7345058-B2 (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome HOFFMANN-LA ROCHE INC. (US) 2008-03-18 — — US disclosed
WO-2007107470-A2 PYRAZOLES AS 11-BETA-HSD-1 F. HOFFMANN-LA ROCHE AG (CH) 2007-09-27 — — WO disclosed
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase ANDERSON KEVIN WILLIAM 2007-09-27 — — US disclosed
WO-2006106052-A1 PYRAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2006-10-12 — — WO disclosed
US-20060223852-A1 Pyrazoles GILLESPIE PAUL 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase HSD3B2, HSD3B1, HSD17B2 CA2 2305/4885CA4 2998/4885CA5A 313/4885
US-20060223852-A1 Pyrazoles GPR119, PDK2, PC CA2 3975/4885CA4 4187/4885CA5A 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.